Findings from the VERTIS-CV trial looking at the safety and efficacy of ertugliflozin, one of the newer sodium-glucose cotransporter 2 (SGLT2) inhibitors, indicate that the drug does not impact the likelihood of heart attack, stroke, or cardiac death in patients with type 2 diabetes. The findings were presented by a panel of the trial investigators, including Christopher P. Cannon, MD, during the Scientific Sessions.
ICYMI: VERTIS-CV trial results support use of SGLT2 inhibitors in type 2 diabetes patients
